FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval

Psychedelic medicine is at the FDA's door with a problem: enthusiasm to address unmet needs, but lack of consensus on execution. At yesterday’s FDA public hearing “Considerations for Potential Therapeutic Use of Psychedelic Drugs,” commentary was—unsurprisingly—mixed. From clinical researchers, pharmaceutical representatives, academic groups, veterans, and cultural groups, statements covered access, clinical usefulness, administration, safety, and more. FDA Deputy Center Director Marta Sokolowska framed the session as part of a “whole of government effort” following the April 2026 executive order on accelerating treatments for serious mental illness, the FDA’s finalized clinical-investigation guidance, and 3 national priority vouchers issued to sponsors studying psilocybin and methylone.^¹ While the hearing explicitly excluded discussion of individual drug applications, the clinical testimony converged on several recurring tensions.

Efficacy Across Indications

Several clinicians spoke directly to therapeutic effect: Christine Caldwell, founder of End of Life Psychedelic Care, cited a case in which psilocybin therapy reduced a stage 4 cancer patient's GAD-7 score from 36 to 6, alongside additional cases of improvement in the palliative population; Amber Barnato, MD (Dartmouth), cited a 2024 Cochrane review showing psilocybin-assisted therapy produces durable reductions in depression, anxiety, and demoralization in people facing life-threatening illness. Barnato also cautioned that the certainty of evidence remains low, drawn from small, functionally unblinded trials.

Real-world data from outside the US also featured. Greg Hutchinson, representing an Australian psychedelic-assisted therapy network reported more than 500 dosing sessions since October 2023 with 12-month follow-up, describing results as "highly encouraging" and durable, with no severe adverse reactions.

Ibogaine drew particular attention as a research focus for trauma and brain injury. Michael Lawton, MD (Barrow Neurological Institute), described the Arizona Ibogaine Trial, which pairs ibogaine with structured integration therapy in veterans with PTSD and traumatic brain injury, using DNA methylation and magnetoencephalography to correlate clinical improvement with measurable brain changes. James Green, MPH (Rutgers), presented supporting pharmacovigilance data: an analysis of more than 610,000 patients with opioid use disorder found that in Medicare populations, nearly 30% of potential ibogaine candidates were taking a medication that would trigger exclusion under current safety protocols—underscoring a gap between identifying cardiac risk and knowing how to clinically manage it.

Who Should Be in the Room?

The widest disagreement centered on administration protocols. Rajan Dunne, MD, a psychiatrist at Sheppard Pratt, argued that “good psychedelic care requires the full scope of psychiatric expertise,” including diagnostic formulation and complication management, and called for mandatory psychiatrist oversight. Nurse practitioner Tina Braddock countered that an existing, licensed nursing workforce is “already here, trained, deployable now.” Several speakers, including Peter Hendricks, PhD (University of Alabama at Birmingham), noted that FDA’s own guidance has not characterized whether psychotherapy contributes independently to efficacy, and urged that credentialing requirements track the evidentiary model each sponsor ultimately supports in labeling, rather than a uniform mandate. Multiple speakers noted that training should be required beyond clinical hours, with a specific assessment to be passed for clinicians administering psychedelics.

Is the Drug or the Encounter the Intervention?

A related thread questioned the issue of isolating pharmacologic effect from psychotherapeutic context. Clinical psychologist Geoff Bathje, PhD, cited controlled-trial data showing therapist warmth outperforming pharmacology alone, and noted that available ketamine and psychedelic comparisons “have confirmed that these substances are more effective with therapy.” Therapist and facilitator witnesses echoed concern that cost pressure could strip the therapeutic relationship from delivery models.

Capturing the Safety Signal

Edward Jacobs, PhD (Oxford), cited a JAMA Psychiatry meta-analysis finding serious adverse events in roughly 4% of trial participants with pre-existing psychiatric conditions, and cautioned that real-world risk is “more likely to be underestimated than overestimated” once trial-level safeguards loosen. Aliya Lilienstein, MD (UC Berkeley), proposed a standardized adverse-event taxonomy modeled on oncology’s CTCAE framework, noting inconsistent classification of subjective effects across current trials. Lawrence Goldkind, MD, formerly of FDA’s Center for Drug Evaluation and Research, urged against templated class-wide REMS, arguing that abuse potential and safety profiles differ meaningfully across compounds.

Further Cautionary Statements

Not all testimony was supportive of psychedelics and an accelerated pathway. Kevin Sabet, PhD (Foundation for Drug Policy Solutions), argued psychedelics “should earn approval the way any other class of drug does—through science and trials, not politics,” citing issues of small trial samples and methodological concerns. A member of the public, whose adult daughter died following psychedelic use, urged that public education on risk accompany any approval, separate from clinical access itself.

Addressing Access and Equity

Rural-access concerns recurred, particularly around guidance requiring physician availability when a nonphysician leads a session—a standard several speakers said could exclude some clinics. Melissa Lavasani, MSc (Psychedelic Medicine Coalition), highlighted the underrepresentation of women in psychedelic research funding and called for capturing reproductive-stage and hormonal data.

Pipeline Context

The hearing occurred as some psychedelic candidates look towards potential approval. Compass Pathways’ synthetic psilocybin, COMP360, has reported durability data through 6 months in treatment-resistant depression and is undergoing a rolling FDA submission.² Definium Therapeutics’ DT120, an LSD-based candidate, recently completed its third positive phase 3 readout, including the latest Panorama trial in generalized anxiety disorder, with a pre-NDA meeting anticipated in late 2026.³

Keep up with developing psychedelic data and regulatory action with Psychiatric Times!

References

1. Davis M, Farchione TR, et al. FDA's new framework for psychedelic drugs. N Engl J Med. 2026;395(10).

2. US Food and Drug Administration. Psychedelic drugs: considerations for clinical investigations. 2026. Accessed September 15, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

3. Kuntz L. Positive topline results from phase 3 Panorama study of DT120 ODT in generalized anxiety disorder. Psychiatric Times. September 14, 2026. https://www.psychiatrictimes.com/view/positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder